The breakthrough offers a beacon of hope for Johnny Lubin, a 15-year-old from Connecticut who has lived with the debilitating effects of the disease.
He inherited the sickle cell gene from both of his parents and has experienced severe pain and health complications since infancy.
Johnny’s parents, Fabienne and J.R. Lubin, were desperate for a solution when they learned about a cutting-edge clinical trial involving gene editing, a process not requiring a donor.
After a challenging five weeks in the hospital and a six-month absence from school, Lubin has drastically improved health and prospects for a longer life.
“I thought that was pretty cool how I have like new cells and I honestly hoped, you know, I could get, you know, some super powers from it, you know, maybe become a superhero, you know, like genetically engineered,” Lubin said.
Gene editing is expected to cost several million dollars per patient and may not be appropriate for everyone who has sickle cell disease.
The original article contains 503 words, the summary contains 162 words. Saved 68%. I’m a bot and I’m open source!
This is the best summary I could come up with:
The breakthrough offers a beacon of hope for Johnny Lubin, a 15-year-old from Connecticut who has lived with the debilitating effects of the disease.
He inherited the sickle cell gene from both of his parents and has experienced severe pain and health complications since infancy.
Johnny’s parents, Fabienne and J.R. Lubin, were desperate for a solution when they learned about a cutting-edge clinical trial involving gene editing, a process not requiring a donor.
After a challenging five weeks in the hospital and a six-month absence from school, Lubin has drastically improved health and prospects for a longer life.
“I thought that was pretty cool how I have like new cells and I honestly hoped, you know, I could get, you know, some super powers from it, you know, maybe become a superhero, you know, like genetically engineered,” Lubin said.
Gene editing is expected to cost several million dollars per patient and may not be appropriate for everyone who has sickle cell disease.
The original article contains 503 words, the summary contains 162 words. Saved 68%. I’m a bot and I’m open source!